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1 Abstract 
One of the major health risks of the Western world today is cardiovascular diseases. Low levels of 
high density lipoprotein cholesterol (HDL-C) are strongly related to the risk of atherosclerotic 
cardiovascular disease. A new cellular cholesterol transporter has been suggested to be of 
potential major importance for HDL formation and reverse cholesterol transport, the half ABC 
transporter, ABCG1. The impact of this gene in human atherosclerotic disease remains to be 
determined. With the aim to identify genetic variation in the ABCG1 promoter, we used a 
systematic approach in which we screened individuals selected from the general population with 
the lowest 2% and the highest 2% levels of HDL-C for age and gender. Twenty-three genetic 
variations were identified, ranging in allele frequency from 0.1 to 28%, and 18 of these have not 
been reported previously. Eight rare variants were exclusively identified in one of the extreme 
HDL-C groups indicating that they might affect HDL-C levels. The present promoter screening 
constitutes the basis for future in vivo and in vitro studies that will determine the role of ABCG1 
for atherosclerosis development in humans and potentially suggest the gene as a target for 
therapeutic interventions. 
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2 Resumé 
Den største helbreds risiko i den vestlige verden i dag er udviklingen af hjertekar sygdomme. Lavt 
niveau af high density lipoprotein kolesterol (HDL-C) er stærkt relateret til dannelse af 
åreforkalkning. En ny cellulær kolesterol transporter er foreslået at være af stor potentiel 
betydning for dannelsen af HDL og revers kolesterol transport, en halv transporter i ABC 
transport familien, ABCG1. Vigtigheden af dette gen for åreforkalkning mangler stadig at blive 
belyst. For at bestemme genetisk variation i ABCG1 promoteren, brugte vi en systematisk strategi 
hvor individer fra den generelle befolkning med det 2 % laveste og 2 % højeste niveau af HDL-C 
sorteret for alder og køn, blev udvalgt. 23 genetiske variationer blev fundet, med allel frekvens fra 
0,1 til 28 % og 18 af disse har ikke været rapporteret før. Otte sjældne variationer var eksklusivt 
fundet i en af de ekstreme HDL-C grupper. Dette indikerer at disse kunne have en effekt på 
HDL-C niveauet. Denne promoter screening vil danne grundlag for fremtidige in vivo og in vitro 
studier der vil kunne bestemme ABCG1s rolle ved udvikling af åreforkalkning hos mennesker. 
Potentielt vil projektet også kunne afklare om ABCG1 kan bruges som target gen for terapeutisk 
intervention.  
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3 Abbreviation list 
ABCA1  ATP-Binding-Cassette transporter A1 
ABCG1  ATP-Binding-Cassette transporter G1 
ABC transporter ATP-Binding-Cassette transporter 
Apo  Apolipoprotein  
CAD  Coronary artery disease 
CCHS  The Copenhagen City Heart Study 
CETP  Cholesteryl-Ester-Transfer-Protein 
ddNTP  Dideoxynucleotidetriphosphates 
dHPLC  Denaturing-High-Performance-Liquid-Chromatography 
dNTP  Deoxynucleotidetriphosphate 
HDL  High-Density- Lipoprotein 
HDL-C  High-Density- Lipoprotein- Cholesterol 
IDL  Intermediate-Density-Lipoprotein  
IVS  Intervening sequence 
LDL  Low-Density- Lipoprotein 
LCAT  Lecithin-Cholesterol-Acyl-Transferase 
LXR  Liver-X-Receptor 
NBF  Nucleotide-Binding-Fold 
NCBI  National Center for Biotechnology Information 
PCR  Polymerase-Chain-Reaction 
RCT  Reverse-Cholesterol-Transport 
RXR  Retinoid-X-Receptor 
SNPs  Single-Nucleotide-Polymorphisms 
SP1  Specificity protein 1 
SR-BI  Scavenger receptor, class B, type I 
TD  Tangier disease 
TEAA  Triethylammonium acetate 
VLDL  Very- Low-Density- Lipoprotein  
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4 Introduction 
One of the major health risks of the Western world today is cardiovascular diseases1. Low levels 
of high density lipoprotein cholesterol (HDL-C) are strongly related to the risk of atherosclerotic 
cardiovascular disease2. The major lipoprotein risk factors are characterised by low levels of 
HDL-C and increased levels of triglycerides and low density lipoprotein cholesterol (LDL-C)3,4. 
Atherosclerosis is a progressive disease characterized by the accumulation of lipids and fibrous 
elements in the large arteries5. The early lesions, called “fatty streaks”, consist of subendothelial 
accumulations of cholesterol-engorged macrophages, the so-called foam cells. Fatty streaks are 
not clinically significant, but they constitute the initial lesion that subsequently develops into more 
advanced changes, characterized by the accumulation of lipid-rich necrotic debris and smooth 
muscle cells. Although advanced lesions can grow sufficiently large to block blood flow and cause 
intermittent ischemic syndromes such as angina pectoris, the most important clinical 
complication is an acute occlusion due to the formation of a thrombus, resulting in a myocardial 
infarction or stroke5. 
In reverse cholesterol transport, efflux of excess cellular cholesterols from arterial wall 
macrophages prevents the macrophage in transforming into foam cells. Several cellular 
cholesterol and phospholipids transporters have been identified, among these ABCA1 and most 
recently ABCG16. In 1999, ABCA1 was identified as the mutated gene in familial HDL 
deficiency syndromes7-9, the homozygous state causing Tangier disease (TD), an autosomal 
recessive disorder of lipid metabolism, whereas the heterozygous state causes the milder familial 
hypoalphalipoproteinemia. Tangier disease is characterised by almost or complete absence of 
HDL-C in plasma as well as accumulation of cholesterol esters in macrophage-rich tissues and 
increased risk of atherosclerosis10. Recently, it was shown that heterozygosity for ABCA1 
mutations was relatively common, when resequencing the lower tail of the HDL-C distribution in 
two independent general population samples11,12. Mutations and single nucleotide polymorphisms 
(SNPs) in ABCA1 also affect HDL-C levels and risk of IHD in the general population12,13.  
A new cellular cholesterol transporter has been suggested to be of potential major importance for 
HDL formation and reverse cholesterol transport, the half ABC transporter, ABCG1. The impact 
of this gene in human atherosclerotic disease remains to be determined. 
 
 
  
4.1 Cholesterol, lipoproteins and apolipoproteins 
Cholesterol and lipids are insoluble in water and must therefore be transported from tissue to 
tissue in carrier particles, lipoproteins. Lipoproteins are spherical complexes with hydrophobic 
lipids in the core and hydrophilic components of apolipoproteins, phospholipids and cholesterol 
esters at the surface (Figure 1).  
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Figure 1: Lipoprotein particle 
(www.peprotech.com).  
Lipids are placed in the core, and different 
apolipoproteins and other hydrophilic 
compounds are placed on the surface. TG 
denotes triglycerides and CE cholesteryl 
esters.  
 
Several lipoprotein classes exist with different contents of apolipoproteins, lipids, enzymes and 
various other proteins. Chylomicrons are the largest and most triglyceride-rich of the lipoprotein 
classes. A decreasing content of triglycerides from chylomicrons through Very Low Density 
Lipoproteins (VLDLs), Intermediate Density Lipoproteins (IDLs), LDLs to HDL corresponds 
with increasing density and protein content. Apolipoproteins (apo) as apoE, apoB and apoA-I are 
involved in a wide range of functions including receptor binding properties and activation of 
enzymes, and furthermore serve as plasmatic acceptor molecules for cellular cholesterols. 
Chylomicrons and VLDL particles pass through a lipolytic process producing particles of 
progressively decreasing size and triglyceride content (IDLs and LDL). Although VLDL and IDL 
contain both apoE and apoB, these particles are cleared mainly through apoE interaction with the 
LDL receptor and LDL receptor-related protein, whereas LDL, which contains only apoB, is 
cleared by interaction of apoB with the LDL receptor. Thus, a progression from apoE to apoB-
mediated clearance via the LDL receptor occurs as VLDL particles pass through the lipolytic 
process and are changed into IDL and LDL particles14,15. Hence, chylomicrons, VLDL, IDL and 
LDL are mainly involved in cholesterol and triglyceride transport between the intestine and the 
liver. In contrast, HDL is the major particle in reverse cholesterol transport where excess cellular 
cholesterols from peripheral tissues are transported to the liver for excretion in the bile or for 
further metabolism via other lipoproteins. HDL contains a different and a larger amount of 
apolipoproteins, e.g. apoA-I, apoC-I, apoE and apoA-II. 
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Figure 2: Overview of HDL metabolism and reverse cholesterol transport (RCT) according to Brewer 16  
FC denotes free cholesterol, PL phospholipids, LRP LDL-related protein, and LPL lipoprotein lipase. 
 
 
In reverse cholesterol transport, peripheral tissues remove their excess cholesterol through 
ABCA1 to poorly lipidated plasmatic apoA-I, forming pre-β-HDL. Subsequently LCAT esterifies 
free cholesterol to cholesterol-esters, converting pre-β-HDL to the mature spherical α-HDL 
particle (Figure 2). The removal of excess cholesterol from peripheral tissues is of critical 
importance in preventing cholesterol accumulation and foam cell formation in macrophages17,18, 
because foam cell formation, as mentioned earlier, is the starting point for an atherosclerotic 
plaque. 
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Cholesterol in the HDL-C particle is transported to the liver by two pathways; (1) it can be 
delivered directly to the liver through interaction with the scavenger receptor, class B, type I (SR-
BI, blue arrow in Figure 2); (2) cholesteryl esters in HDL are transferred by the cholesteryl ester 
transfer protein (CETP) to VLDL and LDL and are then returned to the liver through the LDL 
receptor (red arrows)16.  
ABCG1 mediates the efflux of cellular cholesterol from macrophages to two subclasses of HDL, 
HDL3 and HDL2 particles, but not to lipid-poor apoA-I, Figure 3. HDL3 and HDL2 particles vary 
in densities due to different concentrations of plasma lipoproteins. ABCA1 interacts poorly with 
the HDL2 and HDL3 particles that represent the bulk of plasma HDL6.  
 
 
 
Figure 3: Overview of the major pathways in reverse cholesterol transport from peripheral tissue and 
macrophages; according to Van der Velde and K. Groen 200519. 
ApoA-I is secreted by the liver and intestine and is lipidated with cholesterol and phospholipids by 
interaction with hepatic or intestinal ABCA1 resulting in the formation of pre-β-HDL. In plasma the 
pre-β-HDL particle is converted to HDL2 after it picks up cholesterol and phospholipids from ABCA1 
in macrophages and peripheral cells. Cellular cholesterols can also be effluxed directly to the HDL 
particle by ABCG1 and possibly by SR-BI in macrophages. This efflux is predominantly mediated by 
the HDL2 particle. 
 
The expression of ABCA1 and ABCG1 is induced by the oxysterol-activated transcription factors 
Liver-X Receptor/Retinoid X Receptor (LXR/RXR). When LXR is activated in macrophages, an 
increased efflux of cholesterol to HDL2 and apoA-I is seen, suggesting the presence of unique 
LXR target genes (e.g. ABCA1 and ABCG1) mediating cholesterol efflux to HDL and apoA-I6,20.  
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4.2 ATP-Binding Cassette Transporters  
In humans there are 52 members of the ATP-Binding Cassette (ABC) super family of multipass 
transmembrane transporters that pump specific molecules across extra- and intracellular 
membranes by binding and hydrolysing ATP, which provides the energy for transport21,22. The 
ABC transporters are divided into seven distinct groups; ABCA through ABCG and subdivided 
into full and half transporters22. Full transporters contain two transmembrane domains, where 
each domain typically harbour six hydrophobic membrane spanners and one ABC unit, also 
known as nucleotide binding folds (NBFs). The NBF contains three characteristic conserved 
regions, the Walker A and B domains and a signature motif (linker)22,23. Half transporters contain 
only one transmembrane domain and must therefore either form hetero- or homodimer with 
other ABC transporters to work as a functional pump22,24.  
 
4.2.1 ABCG1 
The human ABCG subfamily consists of six “reverse” half transporters that have a NBF at the N 
terminus and a transmembrane domain at the C terminus. The ABCG1 is also known as ABC8 
and is a homolog to the Drosophila white gene25. The ABCG1 protein is closely related to 
ABCG4 with 94% homology, and is thought to function as both homodimer and heterodimer6,22. 
The ABCG1 gene has been mapped to chromosome 21q22.3 in humans and spans over a 
genomic region of 98 kb. ABCG1 is subject for alternative splicing resulting in seven different 
isoforms. The main transcript consists of 15 exons (see Figure 4) whereas alternative splice 
variants have up to 23 exons. The different transcripts will affect the intracellular and N terminus 
parts of the protein20,25,26.  
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Figure 4: A: Genomic structure of the human ABCG1 gene. B: A model of ABCG1 according to 
Langmann et al. 200025. 
A: The exons are denoted as black boxes. The lower panel shows the relation between coding exons 
and the protein domain organisation of ABCG1. NBD denotes nucleotide binding domain, TM 
transmembrane spanners.  
B: The ABCG1 is an ABC transporter with one transmembrane domain, consisting of six 
hydrophobic membrane spanners. The ABC region consists of the Walker A and B motifs and is 
connected by a family specific signature region (linker).  
 
The function of ABCG1 is not fully known, but different studies have indicated that ABCG1 is 
involved in the efflux of cholesterol to HDL2 (Figure 3). This function is also facilitated by the 
ABC transporter, ABCA1. ABCA1 mediates efflux of cholesterol to lipid poor apoA-I creating 
the nascent pre-β-HDL particle. ABCG1 is thought to mediate the efflux of cholesterol to the 
mature HDL particle instead6,22,27. The expression of ABCG1 mRNA levels has been shown to 
increase in RAW (mouse macrophages) and HepG2 cells when incubated in a medium containing 
high levels of liver X receptor (LXR) agonists and in cholesterol loaded foam cells20,22. LXR is a 
transcription factor and has been shown to activate genes related to cholesterol efflux from 
macrophages28. This may indicate that ABCG1 is involved in the efflux of cholesterol and 
supports ABCA1 in the efflux of cholesterol to HDL6. 
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4.3 Aim 
Primary aim: 
 
To identify genetic variation in the ABCG1 promoter in individuals selected from the general 
population with the lowest 2% and the highest 2% levels of HDL-C for age and gender.  
 
Secondary aim: 
 
To generate a well functioning ABCG1 promoter vector for future site directed mutagenesis 
studies of human variants and transcriptional activity. 
 
5 Methods 
In this section we give a description of the different methods used in the present project. A list of 
materials and equipment is included in Appendix A. Protocols are listed in Appendix C. 
 
5.1 Sample material 
The Copenhagen City Heart Study (CCHS) is a prospective cardiovascular study of 20 to 80+ 
year old individuals selected from the central population register reflecting the adult Danish 
general population29. The CCHS started in 1976 -1978 by inviting 19,329 individuals of which 
74% (14,223) participated. A second invitation was sent out in 1981 - 1983 including the original 
cohort and an additional 500 individuals in the 20 to 25 year span. From this invitation 70% 
participated (12,698). In 1991 – 1994 a third invitation was sent out including the original cohort 
and additional 3,000 individuals aged 20 to 49 years. At the third examination 61% participated 
(10,135) and DNA is available on 9,259 of these individuals29. 
At all three examinations the participants were given a medical and physical examination, a self 
administrated questionnaire and a blood sample was taken for biochemical analysis. At the third 
examination 1991 – 1994, additional blood samples were taken for DNA extraction. For the 
present study, we selected individuals with the lowest 2% (n=190) and highest 2% (n=190) HDL-
C levels corresponding to the 1st, 2nd 99th and 100th percentile for age and gender.  
The cut off levels were as follows for the 2nd percentile (women and men respectively); 20 – 29 
years: 1.0 and 0.8 mmol/L, 30 – 39 years: 0.9 and 0.7 mmol/L, 40 – 49 years: 0.9 and 0.7 
mmol/L, 50 – 59 years: 0.9 and 0.8 mmol/L, 60 – 69 years: 0.9 and 0.7 mmol/L, 70 – 79 years: 
0.9 and 0.8 mmol/L, and 80+ years: 0.9 and 0.7 mmol/L. The cut off levels were as follows for 
the 99th percentile (women and men, respectively); 20 – 29 years: 2.6 and 2.1 mmol/L, 30 – 39 
years: 2.7 and 2.2 mmol/L, 40 – 49 years: 2.8 and 2.3 mmol/L, 50 – 59 years: 3.0 and 2.6 
mmol/L, 60 – 69 years: 3.0 and 2.7 mmol/L, 70 – 79 years: 3.1 and 2.5 mmol/L, and 80+ years: 
2.8 and 2.4 mmol/L. 
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5.2 Primer design 
Design of primers can be done either manually or by entering the sequence into a primer design 
program. Some general rules need to be followed: 
 
• DNA sequence information should be obtained from a reference database. 
• Primers should not be placed less than 30 -50 nucleotides from the ends of the specific 
sequence fragment subjected for amplification.  
• Primers should be 18 – 30 nucleotides in length.  
• Primers should not contain more than 60% GC nucleotides.  
• Avoid primer self-complementarity (in order to avoid primer-dimer and hairpin 
formation). 
• Avoid complementarity between the primers. 
• Avoid complementarity to other genomic regions or primers outside the target region. 
 
We used a primer design programme; Oligo Primer Analysis Software, version 6.6.7.0 (Molecular 
Biology Insights, Inc). 
 
Table 1: List of primers used to amplify the different fragments in the promoter region and exon 1 of ABCG1. 
Primer sequence 
5’ – 3’ Exon 
Forward Reverse 
Gene screening:  
Promotor 1 TTCAGCCAAGTGTAAAATCAAGGTA ACCCACAGGTCAGATGACTGTAACCA 
Promotor 2 CCTCCCACTTAAACTCATAACCGT GAGGTGTTTCCAGAGCCATGTTCA 
Promotor 3 CTGGGGCCACATGGGAG GGCTGTGTGATGGGGTCGAAGA 
Promotor 4 GGGCGTTGGAGTGGTTATCTCT GCAGGTGCGCGTGCTCT 
Exon 1 CCCATGCCGCCTGCGAG TCAGGTCGAGCTTGCGAGTCT 
Functional studies:  
Insert 1 CCCGGTACCCAGGTGTGCTGGAAAT CCCGCTAGCGAGAAAGCGGCCATCAGACA 
Site-directed 
mutagenesis TGCTGGCCCAG T CCCCGCGAG CTCGCGGGG A CTGGGCCAGCA 
 
5.3 PCR and optimisation 
Polymerase chain reaction is a fast in vitro method to amplify a specific region of the genome 
defined by the chosen primer set. The target regions were optimised according to standard 
protocols in the laboratory; two temperatures (57°C and 60°C), four different MgCl2 
concentrations (1 mM – 2.5 mM) and with two different DNA samples. The PCR was run on 
Eppendorf Mastercycler with the following program. 
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Figure 5: Schematic drawing of the PCR program on Eppendorf Mastercycler. 
 
We optimised the promoter region and exon 1 according to these conditions. From visual 
inspection of the PCR fragments on an agarose gel, the optimal temperatures and MgCl2 
concentrations were chosen for each reaction.  
 
5.4 Gel electrophoresis 
Nucleic acids are negatively charged and are thus able to migrate in an electric field; consequently 
the nucleic acids can be separated by charge and size. Agarose gels are commonly used for 
separation of DNA fragment from 0.1 to 25 kb. The migration of DNA fragments is dependent 
on the agarose gel concentration; low concentrations for large fragments and high concentrations 
for small fragments. We used a 1% agarose gel for visualising the PCR fragments with average 
sizes of 400 bp. Before loading the samples, gel-loading buffer was added, which increases the 
density of the fragments and enables the comigration of dye and PCR fragments. The gel is 
stained with ethidium bromide before the gel has set. The ethidium bromide binds to double 
strand DNA and can be visualised with UV light at wavelengths between 254 – 366 nm. A 
molecular marker is loaded in a separate well next to the samples and used to estimate the size of 
fragments. 
 
5.5 Single nucleotide polymorphisms (SNPs) and mutation detection by 
dHPLC 
Denaturing high performance liquid chromatography (dHPLC) is a highly sensitive, inexpensive 
and automated method for screening of new DNA sequence variation (SNPs and mutations)30. 
The detection of sequence variation in DNA by dHPLC relies on UV absorbance 
spectrophotometry, by ion-pair reversed-phase liquid chromatography under partial denaturing 
conditions done within an acetonitrile gradient31. Detection of mutations (minor allele frequency 
< 0.01) or SNPs (minor allele frequency > 0.01 on dHPLC relies on the forming and separation 
of double stranded DNA with a mismatched base pair, denoted heteroduplex.  
The heteroduplex formation is generated by denaturation of the PCR fragments at a temperature 
of 95°C and a slowly cooling which will reanneal the PCR fragments. By adding wild type to a 
sample with a possible mutation the denaturation and reannealing will form a mixture of hetero- 
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and homoduplexes. As the dHPLC cannot differentiate between mutant homoduplex and wild 
type homoduplex, the adding of wild type PCR fragments to each test sample will generate 
heteroduplexes when both heterozygotes and mutant homozygotes are present (Figure 6).  
 
Figure 6: Principle of hetero- and homoduplex formation. 
 
Melting points for heteroduplexes are different than for homoduplexes, due to the mismatched 
base pair. The mismatched bases in the heteroduplex begin to separate from the column before 
the homoduplexes at a given temperature. The separation of the heteroduplexes is dependent on 
two factors: the temperature of the column and the concentration of the acetonitrile (mobile 
phase).  
DNA is negatively charged due to the phosphate ions on the DNA backbone. The DNA 
fragments cannot adsorb to column matrix, because the stationary phase of the column is neutral 
and hydrophobic. By leading ammonium ion of triethylammonium acetate (TEAA) through the 
column, which is positively charged, the TEAA will interact with the DNA backbone and the 
hydrophobic surface of the column. The stationary phase will absorb longer fragments of DNA 
more strongly, than shorter fragments. By increasing the concentration of acetonitrile in the 
mobile phase, the hydrophobic interactions between the stationary phase and the alkyl chains of 
TEAA will be reduced (Figure 7).  
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Figure 7: Interaction of the column with wild type DNA and mismatched DNA. A: The TEAA 
interacts hydrophobically with the cartridge. The positive charge of the triethylammonium ion 
interacts electrostatically with the negative charge of the DNA backbone. B: Acetonitile reduces the 
hydrophobic interaction between the cartridge and alkyle chain of TEAA. C: Partially denatured 
DNA has fewer negative charges, and therefore interacts less strongly with the cartridge, through 
TEAA. D: Fewer acetonitril molecules are required to release the partially denatured DNA from the 
cartridge. 
 
At a specific temperature the heteroduplex fragments are denatured in the region at either side of 
the mismatched bases, which lead to a reduction in the double stranded portion of the PCR 
fragment. The single stranded portion of the fragment, which includes the mismatched bases, has 
reduced number of negative charges compared to the double stranded portion. This leads to an 
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earlier elution of heteroduplexes compared to homoduplexes, which is visualised as an earlier 
peak on the chromatogram.  
The column will elute the DNA fragments in a size- and sequence-dependent manner. To gain 
separation of the injection peak and the homo/heteroduplex from the sample a time shift can be 
added to secure a separation of these peaks. Time shift will delay the retention time of the 
samples so it will be possible to differentiate samples and the injection peaks. 
 
5.6 Sequence analysis 
Samples with a changed elution profile on the dHPLC compared to the wild type were 
subsequently sequenced to establish the DNA sequence variation in the sample. The Sanger 
dideoxy method was used which is based on the controlled interruption of a thermo stabile DNA 
polymerase with a dideoxynucleotidetriphosphate (ddNTP) (Figure 8).  
When the polymerase inserts a ddNTP instead of a normal dNTP (Figure 8) it is not able to 
elongate the DNA strand at the 3’ position of the nucleotide. This releases the polymerase from 
the template and in the next cycle the polymerase will be attached to another DNA strand. After 
each cycle there will be strands of different lengths ranging from one nucleotide to the total 
length of the PCR fragment. This is due to the much lower concentration of the ddNTPs than 
dNTPs; therefore the insertion of ddNTPs is random.  
 
 
Figure 8: The structure of dideoxynucleotidetriphosphate 
(ddNTP) and deoxynucleotidetriphosphate (dNTP). The 
difference between ddNTP and dNTP is OH missing in 
ddNTP. 
 
 
 
5.7 Cell culture 
A human hepatocellular liver carcinoma cell line, HepG2 cells, was used to examine 
transcriptional activity of the wildtype ABCG1 promoter by a luciferase reporter assay25. Cells 
were cultured in Dulbecco´s modified Eagle´s Medium (DMEM) 4500 mg/l glucose and 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin sulphate at 37°C and 
5% CO2.  
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5.8 Construction of reporter plasmids 
Plasmid reporter constructs containing the ABCG1 promoter region were prepared by insertion 
of a genomic sequence into the KpnI and NheI sites of the pGL3-basic vector, Figure 9. The 
genomic sequence was amplified from human genomic DNA with a forward primer consisting of 
KpnI site-tagged sequence and a reverse primer consisting of NheI site-tagged sequence. The 
inserted restriction sites in the promoter region of the ABCG1 gene were induced by the primers 
for Insert 1; see Table 1 and Appendix B.  
 
A 
 
B 
 
Figure 9: pGL3-basic vector circle map: A: vector without ABCG1 promoter inserted. B: vector with ABCG1 
promoter insert. 
LUC+, cDNA encoding the modified firefly luciferase; Ampr, gene conferring ampicillin resistance; FI ori, 
origin of replication. 
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The amplified promoter region of the ABCG1 gene was digested with the restriction enzymes 
KpnI and NheI to generate compatible ends for cloning and was ligated into pGL3-basic vector. 
The resulting plasmids contain the ABCG1 regulatory promoter sequence in the sense orientation 
placed upstream from the reporter firefly luciferase coding sequence (luc+), Figure 9B.  
 
5.9 Transformation  
Transformation of the plasmids was performed in XL1-Blue super competent cells after 
restriction digestion and ligation of the promoter region sequence in the pGL3-Basic vector.  
The inoculated colonies with the plasmid were purified using minipreperation and 
maxipreperation (Appendix C) from Qiagen® (West succex, Great Britain) and Jetstar® (Löhne, 
Germany). To identify the correct clones containing the ABCG1 promoter the DNA from 
inoculated clones was digested with the restriction enzymes KpnI and NheI to visualise the two 
bands, which would indicate that the insert had been properly introduced into the vector. 
Subsequently, sequencing was performed on these clones to verify the correct sequence (Section 
5.6).  
 
5.10 Site-directed mutagenesis 
To introduce a single nucleotide substitution in the ABCG1 promoter insert the QuikChange® II 
XL-site-directed mutagenesis kit (Stratagene, California, USA) was used as indicated by the 
supplier for the introduction of a base substitution. The target site is a SP1 (specificity protein 1) 
binding site (-376 C>T) in the ABCG1 promoter region.  
 
The QuikChange® II XL-site-directed mutagenesis method relies on linear amplification of 
template plasmid by PfuTurbo DNA polymerase (low error rate). The mutation is incorporated 
in newly synthesised plasmids by the mutagenic primers: 
 
Primer (F): 5’ TGCTGGCCCAG T CCCCGCGAG  
Primer (R): 5’ CTCGCGGGG A CTGGGCCAGCA 
 
Treatment with the enzyme DpnI ensures that only the parental strands are digested (dam-
methylated). This will leave the mutated plasmid to be transformed into XL1-blue competent 
cells. The bacterial ligase repairs the nicks in the mutated plasmid and allows normal replication 
to occur.  
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Figure 10: Principle of the QuikChange® II XL site-directed mutagenesis: 
Two complementary primers with the mutagenic site incorporated is used to introduce the desired 
mutation. After temperature cycles the newly synthesised strands are digested with Dpn I so only the 
mutated strands are transformed into XL1-blue super competent cells (Stratagene, California, USA).  
 
5.11 Transfection and luciferase analyses 
After cloning of the wild type ABCG1 promoter insert into the pGL3 basic vector (Figure 9A), 
transfection into HepG2 cells was performed and luciferase activity was measured. HepG2 cells is 
plated into 24-well dishes containing 175000 cells per well. Twenty four hours after plating, each 
well received a solution containing purified pGL3-ABCG1 plasmid with the firefly luciferase 
reporter gene, pRL-null vector with the Renilla luciferase reporter gene as control for variations in 
transfection efficiency and cell number, and last Fugene 6 reagent. After 24 hours the cells are 
washed with PBS and lysed in 1X Passive Lysis Buffer (PLB) and assayed by the Dual Luciferase 
Assay kit (Promega, Birkeroed, Denmark) in a MicroLumat Plus LB 96V luminometer. Results 
are expressed as the ratio between firefly and Renilla light units.  
The measurements of the ABCG1 promoter activity in the luciferase assay vector are done at 
three selected concentrations of wild type DNA and of 2 different concentrations of pRL-null 
vector plasmid. The three different concentration of wild type DNA were 0.1, 0.2 and 0.5 µg and 
for the endogeneous control (Renilla) we used 0.1 and 0.2 µg. All measurements were done as 
duplicates. Positive (pGL3 control) and negative (pGL3 basic) controls were included at all 
concentrations (Figure 13). 
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A 
 
B 
Figure 11: Vector circle map: pGL3-control vector and pRL-null Vector 
A) The pGL3-control vector consists of the same elements as the pGL3 basic vector and a promoter and 
an enhancer sequence. 
B) The pRL-null vector consists of Rluc, cDNA encoding the modified Renilla luciferase; Ampr, gene 
conferring ampicillin resistance; ori, origin of replication in E. coli (Promega, Birkeroed, Denmark). 
 
The pRL-null Vector contains a cDNA encoding Renilla luciferase which was originally cloned 
from the marine organism Renilla reniformis and contains no enhancer or promoter elements but 
instead a cloning region upstream of Rluc to allow the cloning of any desired regulatory element 
to drive expression of Renilla luciferase. Like firefly luciferase the enzyme may function as a 
genetic reporter following translation. As the Renilla does not contain any promoter or enhancer 
it does not compete for transcription factors. The Renilla vector has a liner relationship to the 
concentration of the vector. This makes it a control for transfection efficiency regardless the lack 
of promoter or enhancer32. The pRL-null Vector (Figure 11) is used in combination with pGL3-
Basic vector to cotransfect HepG2 cells as an endogenous control (Appendix D).  
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Individuals in the low HDL-C group had lower levels of apoAI, higher levels of triglycerides, 
were more obese and had more often diabetes than individuals in the high HDL-C group. 
Twenty-three genetic variations were identified in the promoter region and exon 1 of ABCG1. 
Allele frequencies ranged from 1 of 760 alleles (0.001) to 210 of 760 alleles (0.28) in the low and 
high HDL-C groups (Table 3). Nine SNPs, (allele frequency >1%) were identified in both HDL-
C groups, and four of these have been reported previously (dbSNP 4920072, dbSNP 564010, 
dbSNP 2234714 and dbSNP 2234715). Two common insertion/deletion (indels) polymorphism 
were identified in both HDL-C groups and the most common of these has been reported before 
(dbSNP 603076). Twelve mutations (allele frequency ≤1%) were identified, whereof 2  
(-1091G>A, -224C>T) exclusively were identified in the low HDL-C group, 6 (-1530G>A,  
-686G>A, -438T>G, -372C>T, -269G>A, -209C>T) exclusively identified in the high HDL-C 
group and 4 (-1082C>T, -376C>T, -311T>A, -23insGCC) identified in both groups. None of the 
variants differed significantly (P < 0.05) in frequency between individuals with low and high 
HDL-C levels.  
The present large scale screening of 380 individuals with extreme levels of HDL-C has revealed 
18 new genetic variants and confirmed the presence of five previously reported variants. Two 
genetic variants (-376C>T and -217C>A) were located in known binding sites for the 
transcriptional regulators SP1 and AP-2. The -376C>T mutation seemed to be over-represented 
in the low HDL-C group, and was therefore selected for test of transcriptional efficiency in a 
luciferase reporter system. 
6.2 Genetic variation in the promoter and exon 1 of ABCG1 
 
Characteristics of individuals from the low and high HDL-C groups are shown in Table 2.  
6.1 Characteristics of participants 
6 Results 
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Table 2: Characteristics of individuals from the general population with the lowest 2% and the highest 
2% HDL-C levels for age and gender.  
 Low HDL-C 
(n=190) 
High HDL-C 
(n=190) 
 Men Women Men Women 
Age (yr) 58±1.7 58±1.5 58±1.7 58±1.5 
Sex (%) 44 56 44 56 
Total Cholesterol (mmol/l) 6.1±0.3 6.0±0.5 6.1±0.1 6.7±0.1 
ApoB (mg/dl) 86 ±2.3 95 ±2.7 65 ±2.0 70 ±2.1 
ApoA-I (mg/dl) 86±1.8 97 ±1.3 195±2.6 216±2.6 
HDL (mmol/l) 0.6±0.01 0.8±0.01 2.8±0.05 3.2±0.04 
Triglycerides (mmol/l) 6.8±1.0 3.1±0.2 1.3±0.2 1.4±0.2 
Diabetes (%) 25 ** 8 * 6 2 
BMI (kg/m2) 29 ±0.5 27 ±0.4 24 ±0.5 23 ±0.3 
** P = 0.001; for men, * P = 0.048; for women. 
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Table 3: Genetic variation in the core promoter and exon 1 of ABCG1 in individuals from the general population with extreme HDL-C levels 
Nuber of alleles 
(allele frequency) 
Gene region 
Nucleotide 
substitutionA) Low HDL-C 
(n=380) 
High HDL-C 
(n=380) 
Domain P-value Reference 
Promoter -1560G>A 67 (0.18) 66 (0.17)  1.00 New 
Promoter -1530G>A 0 (0) 1  (0.003)  1.00 New 
Promoter -1523C>T 54 (0.14) 52 (0.14) 1st base of promoter 1.00 New 
Promoter -1452C>G 54 (0.14) 53 (0.14)  1.00 New 
Promoter -1397A>T 50 (0.13) 53 (0.14)  0.83 dbSNP 4920072 
Promoter -1091G>A 1  (0.003) 0 (0)  1.00 New 
Promoter -1082C>T 3  (0.008) 2  (0.005)  1.00 New 
Promoter -841T>C 101 (0.27) 109 (0.29)  0.57 dbSNP 564010 
Promoter -768G>A 92 (0.24) 99 (0.26)  0.62 dbSNP 2234714 
Promoter -686G>A 0 (0) 1  (0.003)  1.00 New 
Promoter -530A>G 23 (0.06) 22 (0.06)  1.00 dbSNP 2234715 
Promoter -438T>G 0 (0) 1  (0.003)  1.00 New 
Promoter -376C>T 3  (0.008) 1  (0.003) SP1 site 0.624 New 
Promoter -372C>T 0 (0) 1  (0.003)  1.00 New 
Promoter -367G>A 46 (0.12) 47 (0.12)  1.00 New 
Promoter -311T>A 1  (0.003) 2  (0.005)  1.00 New 
Promoter -269G>A 0 (0) 1  (0.003)  1.00 New 
Promoter -224C>T 1  (0.003) 0 (0)  1.00 New 
Promoter -217C>A 16 (0.04) 16 (0.04) AP-2 site 1.00 New 
Promoter -209C>T 0 (0) 1  (0.003)  1.00 New 
Promoter -26delGCCGCC * 48 (0.13) 53 (0.14)  1.00 dbSNP 603076 
Promoter -23insGCCGCC ** 14 (0.037) 13 (0.034)  1.00 New 
Promoter  -23insGCC *** 1 (0.003) 2 (0.005)  1.00 New 
* -26delGCCGCC corresponds to the deletion of two GCC repeats out of the most common 10 GCC repeats 
** -23insGCCGCC corresponds to the insertion of two GCC repeats out of the most common 10 GCC repeats 
*** -23insGCC corresponds to the insertion of one GCC repeats out of the most common 10 GCC repeats 
A) +1 denotes A in the start codon ATG corresponding to base position 4455 in sequence AJ289137. Langmann et. al25.  
 
 6.3 Functional effect of the ABCG1 promoter region  
6.3.1 Transfection and identification of clones  
After incorporation of the ABCG1 insert we found that of 32 inoculated colonies only one 
third had the correct insert (Figure 13). One of these wild type clones harbouring the insert 
was used for further experiments.  
 
 
Figure 12: Gel electrophoresis of the inoculated colonies after digest with KpnI and NheI. The size of 
the insert is 1080 nucleotides.  
 
6.3.2 Luciferase analysis 
We found that the wild type ABCG1 promoter will induce approximately a 17 fold  
(15.1 – 19.7) increase in the activity in the concentration range 0.2 µg to 0.5 µg compared to 
the basic vector (Figure 13).  
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Figure 13: The ABCG1 promoter activity of the luciferase gene at 2 different concentrations of pRL-
null vector plasmid and at three selected concentrations of wild type DNA. All measurements were 
done as duplicates. Positive (control) and negative (basic) controls were included at all concentrations.
 
6.3.3 Site-directed mutagenesis 
A correct clone containing the substitution of cysteine in position -376 to thymine done by 
site-directed mutagenesis was obtained for further experiments.  
 24
 7 Discussion 
With the aim to identify genetic variation in the ABCG1 promoter, we used a systematic 
approach in which we screened individuals selected from the general population with the 
lowest 2% and the highest 2% levels of HDL-C for age and gender. Twenty-three genetic 
variations were identified, ranging in allele frequency from 0.1 to 28%, and 18 of these have 
not been reported previously. Eight rare variants were exclusively identified in one of the 
extreme HDL-C groups indicating that they might affect HDL-C levels.  
The extreme group screening approach was chosen to increase the likelihood of identifying 
genetic variants that affect HDL-C levels in the general population, and has been proven 
valid for another HDL-C gene, the ABCA1 gene11,12 and for the APOAV gene, involved in 
triglyceride metabolism33. The characteristics of the extreme HDL-C groups (Table 2) 
illustrate that these individuals are heterogeneous. We chose initially, after careful 
consideration, to select extreme HDL-C groups for the ABCG1 screening solely based on 
HDL-C levels adjusted for sex and age, because previous studies have revealed that the 
application of a set of selection criteria, i.e. normal triglyceride levels and non-diabetic status 
would not have detected most probands12.  
Alternative splicing of ABCG1 has been reported by several groups but the functional 
consequences of these different splice variants are not known. The C terminus of ABCG1 is 
well conserved across the different isoforms and among the reported additional exons26. The 
expression of ABCG1 is primarily found in the lever, spleen, kidney, lung, placenta, skeletal 
muscle and the heart21. The variable N terminus, caused by alternative splicing, may act as a 
localising signal and direct ABCG1 to the target tissue.  
ABCG1 appears to be involved in efflux of cholesterol to HDL26. It is unclear if other 
pathways could compensate for the decreased efflux of cholesterol due to a defect transport 
system or decreased expression of ABCG1. ABCA1 mediates efflux of cholesterol to lipid-
poor apoA-I, and it is possible that ABCG1 could compensate with a larger efflux of 
cholesterol from macrophages to HDL when ABCA1 is not working normally. Since 
ABCG4 is closely related to ABCG1 it is possible that ABCG4 could compensate for a 
defect ABCG16.  
The screening by dHPLC was used as an inexpensive and fast method to pick out the 
individuals with possible variations. Fasano et. al. and other groups have previously reported 
a sensitivity of 97% for dHPLC analysis31,34. As described in section 5.5 the elution of PCR 
fragments is size and sequence-dependent. This will give a difference in elution time for 
homozygote and heterozygote variations (homoduplex and heteroduplex). It is however 
difficult to distinguish between homozygote wild type and homozygote mutations especially 
when the binding energy between wild type- and variation-nucleotides is closely related. For 
this reason the difference between homoduplex and heteroduplex is greater and easier to 
distinguish. This is why the addition of wild type DNA to all samples and heating and slowly 
cooling with formation of both hetero- and homoduplexes, makes it possible to detect  
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homozygote variations. Consequently, both heterozygote and homozygote carriers of the 
rare allele can be detected with this screening approach. 
Functional studies of the ABCG1 promoter is a method to detect if selected variations would 
have an effect on the activity of the ABCG1 promoter. This is done with a luciferase reporter 
vector with an ABCG1 promoter insert. In this study we constructed a well-functioning 
wildtype ABCG1 vector that expressed similar activity as shown previously by others25. We 
experienced that the digestion and ligation was not very efficient when introduced into the 
pGL3 vector. After restriction digest and gel electrophoresis of DNA from more than 30 
colonies we found that only one third of inoculated colonies contained the ABCG1 
promoter insert.  
Langmann et. al. and Sabol et. al. have described the localisation of different regulatory sites in 
ABCG1. Sabol et. al. found three LXR response elements (LXRE) one located in intron 1 
and two in intron two. LXR can activate the promoter of ABCG1 and increase the amount 
of mRNA produced by the activated cell20. Mutations in the LXRE might affect the binding 
of LXR to these sites and subsequently reduce the activation of ABCG120. Since these 
elements could have an effect on the expression of ABCG1 the genetic variations in these 
regions could be of importance.  
It is suggested that three SP1 binding sites are contained in the promoter region (-184, -382 
and -566) as is often seen in core promoters of TATA-less genes25. The SP transcription 
factor family consists of four members (SP1 to SP4). SP1 is a general transcription factor and 
binds to GC boxes. SP1 is seen acting as both an activator and a repressor of various genes. 
The SP3 and SP1 can have competitive binding to different SP1 regions35. Studies by 
Langmann et. at. indicate the presence of silencing elements that mediates functional 
transcriptional repression in the promoter region of ABCG1 upstream from -234. This 
region contains two SP1 sites, a SRB and a NFκB site25 (Appendix B). In the luciferase assay 
we obtained approximately the same expression of wild type ABCG1 promoter as Langmann 
et. al.25. Consequently, our larger ABCG1 insert does not seem to include major unknown 
regulatory elements that alter transcriptional activity. The identified genetic variant in the SP1 
binding site (-376C>T), could potentially affect the level of transcription due to the 
competitive binding of SP1 and SP3. The -376C>T variant might affect the binding of SP1 
and increase the binding of SP3 as a stronger repressor.  
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 8 Conclusion 
By screening the ABCG1 promoter, 23 genetic variations were identified, ranging in allele 
frequencies from 0.1 to 28%, and 18 of these were new. The different distribution of eight 
rare variants in low and high HDL-C groups indicates that they might affect levels of HDL-
C in plasma. Future large scale genotyping of the entire CCHS cohort and transcriptional 
activity assays will reveal the in vivo and in vitro effects of the genetic variation identified in 
the present work.  
 
 
9 Perspective 
Atherosclerosis is a multifactorial disease and the development can be caused by several 
factors such as genetic variations, environmental influence, obesity or diabetes. ABCG1 is a 
new cholesterol transporter potentially of major importance in reverse cholesterol transport 
and hence in the prevention of atherosclerosis. The consequence of genetic variation in 
ABCG1 needs to be described before the role of this gene for development of 
atherosclerotic diseases can be determined. In this study we present the genetic variation in 
humans in the regulatory promoter part of ABCG1. The present promoter screening 
constitutes the basis for future in vivo and in vitro studies that will determine the role of 
ABCG1 for atherosclerosis development in humans and potentially suggest the gene as a 
target for therapeutic interventions. 
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 Appendix A 
 
• List of materials and equipment 
 
 
 
 i
 Materials  
 
Chemical and reagents: 
 
PCR: 
AccuPol DNA polymerase (Ampliqon, Bie & Berntsen A/S), 2.5 units/μl  
10 x Ammonium Reaction Buffer (Magnesium- and Tween free) (Ampliqon, Bie & Berntsen A/S) 
MgCl2 solution (Ampliqon, Bie & Berntsen A-S), 25 mM 
dNTPs stock solution (Roche): 100 mM dATP. 100 mM dCTP, 100 mM dGTP, 100 dTTP. 
dNTPs work solution: 25 mM dATP, 25 mM dCTP, 25 mM dGTP, 25 dTTP. 
Primers stock solution (MWG): 100 μM 
Primer work solution: 10 μM 
 
Gel elctrophresis: 
TBE buffer 10 x ultra pure stock (Life technologies): 1 M Tris, 0.9 M boric acid, 1 mM EDTA. 
TBE work solution x 0.5. 
Agarose ultra pure (Life technologies). Agarose work solution: 1% in TBE buffer. 
Ethidiumbromide stock (Life technologies): 10 mg/ml. Ethidiumbromide work solution: 0.1% 
Loading buffer: 50% glycerol, 1 mM EDTA-Na2 (Merck), 0.075 g bromophenol blue (Kebo), 0.075 
g xylene-cyanol FF (SIGMA), add H2O to 50 ml.  
1 kb length marker (Life technologies): 200 μl loading buffer, 188 μl 1 kb length standard, 1112 μl 
H20. 
 
dHPLC: 
DNAsep® HT cartridge (Transgenomic, Inc.) 
Acetonitril 99.93% HPLC grade (Aldrich), TEAA buffer (Transgenomic, Inc.) 
Buffer A: 50 ml TEAA buffer, add H20 to 1 L. 
Buffer B: 50 ml TEAA buffer, 250 ml acetonitril, add H20 to 1 L. 
Buffer C: 80 ml acetonitril, add H20 to 1 L. 
Buffer D: 750 ml acetonitril, add H20 to 1 L. 
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 DNA sequencing: 
ABI PRISM® BigDye® Terminator v1.1 Cycle Sequencing Kit (AB Applied Biosystems). 
 
Ethanol precipitation: 
3M NaAc, pH 5.2 (Merck) 
Ethanol 100% (Merck) 
Ethanol 70% (H:S Apotek) 
 
Restriction digestion: 
10XNebuffer 1 (New England Biolabs) 
KnpI (New England Biolabs) 
NheI (New England Biolabs) 
 
Ligation: 
10XT4 buffer (Roche) 
T4 DNA Ligase (1 Unit/μl) (Roche) 
pGL3-Basic Vector (Stratagene) 
 
Transformation: 
XL1-Blue competent cells (Stratagene) 
LB-medium (with ampicillin) 
LB-medium (without ampicillin) 
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 Minipreperation: 
Buffer P1 with RNase (Qiagen) 
Buffer P2 (Qiagen) 
Buffer N3 (Qiagen) 
Buffer PB (Qiagen) – not required when XL1-Blue cells has been used 
Buffer PE (Qiagen) 
 
Maxipreperation: 
Buffer E4 (Jetstar) 
Buffer E1 (Jetstar) 
Buffer E2 (Jetstar) 
Buffer E3 (Jetstar) 
Buffer E5 (Jetstar) 
Cold isopropanol 
Buffer E6 (Jetstar) 
70% ethanol  
 
Transfection: 
FuGene 6 Reagent (Stratagene) 
Serum free medium (Gibco) 
pGL3-Control Vector (Stratagene) 
pRL-null Vector (Stratagene) 
 
Lysis of transfected cells: 
PBS 
PLB reagent 
1XPLB solution (prepared from 5XPLB stock solution) 
 
 3
 Equipment 
 
 
PCR: 
Apparatus: Eppendorf Mastercycler®  
Utensils: Pipet tips, 1.5 ml Eppendorf tubes, microtiter plates 
 
Gel electrophresis: 
Apparatus: Power supply, cables, gel sledge, electrophresis chamber, photo equipment, UV lamp. 
Utensils: Pipette tips 
 
dHPLC: 
Apparatus:  Wawe® System 
Utensils: Pipette tips, 96-Microtiter plates (Transgenomic, Inc.) 
 
Sequencing: 
Apparatus: Eppendorf Mastercycler® 
Utensils: Pipet tips, 0.5 ml Eppendorf tubes 
 
Sequence product purification: 
Apparatus: Eppendorf centrifuge, concentrator 5301 
Utensil: 0.5 ml Eppendorf tubes 
 
Sequencing: 
Apparatus: AB (Applied Biosystems) 3730 DNA Analyzer 
 
Restriction digestion: 
Apparatus: Incubator (37°C) 
Utensil: 0.5 ml Eppendorf tubes 
 
 
 4
 Ligation: 
Apparatus: Incubator (16°C) 
 
Transformation: 
Apparatus: Incubator (37°C and 45°C)  
Utensil: Pipette tips, 1.5 or 2 ml Eppendorf tubes 
 
Inoculation for Minipreperation: 
Apparatus: Incubator (37°C) with shaking 
Utensil: Pipette tips, culture tubes 
 
Minipreperation: 
Apparatus: Table-top microcentrifuge 
Utensil: Pipette tips, microcentrifuge tubes, QIAprep spin columns, 1.5 ml Eppendorf tubes 
 
Maxipreperation: 
Apparatus: Centrifuge 
Utensil: Pipette tips, centrifuge tubes, columns, 1.5 ml Eppendorf tubes, gaze  
 
Transfection: 
Apparatus: - 
Utensil: Pipette tips, 1.5 ml Eppendorf tubes (sterile), 24-wells culture plate.  
 
Lysis of transfected cells: 
Apparatus: Rocking platform or orbital shaker, -20°C freezer 
Utensil: Pipette tips, 1.5 ml Eppendorf tubes, gaze 
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 Appendix B 
 
• Standard sequence from NCBI acc no. AJ289137 
• The following has been drawn onto the sequence: Exon 1, promoter region and 
transcription factor binding site.  
According to Langmann et. al. Genomic organization and characterization of the 
promoter of the human ATP-binding cassette transporter-G1 (ABCG1) gene. BBA, 
2000  
• Sequence with the primers for exon1 and promoter and the detected variations. 
 ii
  Appendix C 
 
• Protocol for polymerase chain reaction (PCR) 
• Protocol for SNP analysis (dHPLC) 
• Protocol for Sequence analysis 
• Protocol for digestion and ligation (New England Biolabs) 
• Protocol for minipreperation (Qiagen) 
• Protocol for maxipreperation (Jetstar) 
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 Protocol for polymerase chain reaction (PCR) 
Date:   Done by: 
Exon:    
 
Barcode:  Temp: °C 
Reagents Conc.  Final conc.  x 1 µl 
H2O    28.2 µl 
Buffer x 10 x 1  5 µl 
dNTP  (2.5 mM) 0.2 mM  4 µl 
MgCL2  (25 mM) 1 mM  2 µl 
Primer F & R  (10 µM) 0.5 µM  5 µl 
Enzym  2.5 U/µl 2 U/50 µl  0.8 µl 
     
DNA   5 µl 
 
 
Protocol for polymerase chain reaction (PCR) – with Betaine 
 
Date:   Done by:  
Exon:    
Barcode:  Temp: °C 
 
Reagents Conc. Final conc.  x 1 µl 
H2O    28.2 µl 
Buffer x 10 x 1  5 µl 
dNTP  (2.5 mM) 0.2 mM  4 µl 
MgCL2  (25 mM) 1 mM  2 µl 
Betaine 5 M 1.5 M  15 µl 
Primer F & R  (10 µM) 0.5 µM  5 µl 
Enzym  2.5 U/µl 2 U/50 µl  0.8 µl 
     
DNA   5 µl 
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 Protocol for SNP analysis (dHPLC) 
 
Exon PCR dHPLC  Notes 
ABCG1 
MgCl2
(mM) 
Enzym 
Temp. 
(°C) 
Temp. 
(°C) 
Time shift 
(min.) 
WT  
Promotor 1 1 AccuPol 60 - - 3 
 
 
Promotor 2 1 AccuPol 60 
58.4 
60.2 
 
0.4 
5 
 
Promotor 3 1 AccuPol 60 - - 3 
Add 15 µl betaine 
to each sample 
Promotor 4 1 AccuPol 60 
64.3 
66.7 
0.2 
0.8 
3 
 
Exon 1 1 AccuPol 60 - - 4 
 
Add 15 µl betaine 
to each sample 
Fragments not containing temperatures in dHPLC columns were sequenced in all samples. 
Betaine was used to stabilise the PCR reaction.  
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Protocol for Sequence analysis 
Reagents Mix - x1 
H2O 12 µl 
Sekvens buffer 3 µl 
Big dye 2 µl 
Primer 1 µl 
Template 2 µl 
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 Protocol for digestion and ligation (New England Biolabs) 
 
Restriction digestion of PCR product and pGL3 basic vector with restrictions enzynes NheI 
og KpnI. 
 
Digestion of PCR product: 
5 µl 10x Nebuffer 1 
1 µl KpnI 
1 µl NheI 
43 µl PCR product  
Total: 50 µl (mix gently) - Incubate 37°C for one hour. 
 
Digestion of pGL3 basic vector: 
5 µl 10x NEBbuffer 1 
1 µl KpnI 
1 µl NheI 
2 µl vector from maxiprep (app. 1 µg)  
41 µl H2O 
Total: 50 µl (mix gently) - Incubate 37°C for one hour.  
 
Ligation: 
3 µl 10X T4 buffer 
1 µl T4 DNA ligase 
1 µl pGL3 basic vector  
9 µl digested insert (PCR product) 
16 µl H2O 
Total: 30 µl (mix gently) - Incubate 16°C over nigth.  
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 Protocol for minipreperation (Qiagen) 
 
Plasmid DNA Purification Using the QIAprep Spin Miniprep Kit and a 
Microcentrifuge.  
This protocol is designed for purification of up to 20 μg of high-copy plasmid DNA from 1–5 ml 
overnight cultures of E. coli in LB (Luria-Bertani) medium. For purification of low-copy plasmids and 
cosmids, large plasmids (>10 kb), and DNA prepared using other methods, refer to the 
recommendations on page 44. 
 
Please read “Important Notes” on pages 15–21 before starting. Note: All protocol steps 
should be carried out at room temperature. Procedure 
 
1.  Resuspend pelleted bacterial cells in 250 μl Buffer P1 and transfer to a 
microcentrifuge tube. 
Ensure that RNase A has been added to Buffer P1. No cell clumps should be visible 
after resuspension of the pellet. If LyseBlue reagent has been added to Buffer P1, 
vigorously shake the buffer bottle to ensure LyseBlue particles are completely 
dissolved. The bacteria should be resuspended completely by vortexing or pipetting 
up and down until no cell clumps remain. 
2.  Add 250 μl Buffer P2 and mix thoroughly by inverting the tube 4–6 times. 
Mix gently by inverting the tube. Do not vortex, as this will result in shearing of 
genomic DNA. If necessary, continue inverting the tube until the solution becomes 
viscous and slightly clear. Do not allow the lysis reaction to proceed for more than 5 
min. If LyseBlue has been added to Buffer P1 the cell suspension will turn blue after 
addition of Buffer P2. Mixing should result in a homogeneously colored suspension. 
If the suspension contains localized colorless regions or if brownish cell clumps are 
still visible, continue mixing the solution until a homogeneously colored suspension is 
achieved. 
3.  Add 350 μl Buffer N3 and mix immediately and thoroughly by inverting the 
tube 4–6 times. 
To avoid localized precipitation, mix the solution thoroughly, immediately after 
addition of Buffer N3. Large culture volumes (e.g. ≥5 ml) may require inverting up to 
10 times. The solution should become cloudy. If LyseBlue reagent has been used, the 
suspension should be mixed until all trace of blue has gone and the suspension is 
colorless. A homogeneous colorless suspension indicates that the SDS has been 
effectively precipitated. 
4.  Centrifuge for 10 min at 13,000 rpm (~17,900 x g) in a table-top 
microcentrifuge. 
A compact white pellet will form. 
5.  Apply the supernatants from step 4 to the QIAprep spin column by decanting 
or pipetting. 
6.  Centrifuge for 30–60 s. Discard the flow-through. 
7.  Recommended: Wash the QIAprep spin column by adding 0.5 ml Buffer PB 
andcentrifuging for 30–60 s. Discard the flow-through. 
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 This step is necessary to remove trace nuclease activity when using endA+ strains such 
as the JM series, HB101 and its derivatives, or any wild-type strain, which have high 
levels of nuclease activity or high carbohydrate content. Host strains such as XL-1 
Blue and DH5α™ do not require this additional wash step. 
8.  Wash QIAprep spin column by adding 0.75 ml Buffer PE and centrifuging for 
30–60 s. 
9.  Discard the flow-through, and centrifuge for an additional 1 min to remove 
residual wash buffer. 
Important: Residual wash buffer will not be completely removed unless the flow-
through is discarded before this additional centrifugation. Residual ethanol from 
Buffer PE may inhibit subsequent enzymatic reactions.  
10.  Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute 
DNA, add 50 μl Buffer EB (10 mM Tris·Cl, pH 8.5) or water to the center of 
each QIAprep spin column, let stand for 1 min, and centrifuge for 1 min. 
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 Protocol for maxipreperation (Jetstar) 
 
The JETSTAR 2.0 Maxi columns are delivered with the Lysate Filter 
Unit (LFU) inserted into the column housing. 
 
Place the JETSTAR 2.0 column into a suitable rack and equilibrate the column with 30 ml of 
equilibration buffer E4 by pouring the buffer directly into the filter device.  
 
The equilibration buffer will go through the filtration matrix thereby pre-wetting it. Then the buffer will pass through 
the JETSTAR resin and equilibrate it. The column will start dripping. While column equilibration is in process, 
harvest the bacterial cells and prepare the cleared lysate as described below. Shortly after the column has begun dripping, 
some drops at the outlet may appear turbid. This is normal and due to the interaction of the equilibration buffer with 
the matrix. The turbid drops will not affect the preparation in any way. 
 
1.)  Spin down the bacterial cells from the E. coli culture for 3 min at ³12,000 x g. Remove 
the supernatant quantitatively with a pipet. 
 
2.)  Resuspend the cells in 10 ml buffer E1 (reconstituted with 100 μg/ml RNase). No 
cell clumps must be visible. 
If working with >200 ml of bacterial culture, double the volume of buffer E1 and also o buffers E2 
and E3 as outlined in the following steps. 
IMPORTANT: The volumes of buffers E1, E2 and E3 in the kits are for the designated 
number of standard preparations with 10 ml of each buffer. The required volumes of these buffers are 
higher for elevated culture volumes in order to ensure optimal cellular lysis. So, if more buffer E1, E2 
and E3 is required, this additional buffer either has to be purchased separately or prepared by the 
respective user (buffer compositions see below). 
 
3.)  Lyse the bacterial cells with 10 ml buffer E2. Mix gently but thoroughly (e.g. by 
multiple inverting) until a homogeneous mixture is obtained. DO NOT 
VORTEX!!! Due to the release of genomic DNA the mixture is very viscous at this 
stage. Incubate at room temperature for 5 min. 
 
4.)  Neutralize the lysis mix from step 4 with 10 ml buffer E3. 
Mix gently but thoroughly (e.g. by multiple inverting) until a homogeneous mixture 
is obtained. DO NOT VORTEX!!! The liquid of the neutralized lysate must be 
completely nonviscous again. No remainders of the viscous matter obtained after 
lysis of the cells (step 4) must be left. 
 
5.)  Apply the neutralization mix from step 5 with all the precipitated matter in it 
into the Lysate Filter Unit (LFU) inserted into the previously equilibrated (step 
1) JETSTAR / LFU column. Let the lysate run through by gravity flow until 
the flow stops or dripping becomes very slow (< 1 drop per 10 seconds). Do not 
force out any remaining liquid! 
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 OPTIONAL: The final DNA yield can be somewhat improved when residual 
bacterial lysate that remains within the debris particles is washed out by applying 10 ml 
of buffer E5 into the filtration device as soon as gravity flow has stopped or became 
very slow. If buffer E5 is used to wash out residual lysate, let the buffer flow through 
the column by gravity flow until the flow stops or dripping becomes very slow (< 1 
drop per 10 seconds). Proceed to step 7. 
 
6.)  As soon as the JETSTAR column has stopped dripping, take the filtration device out 
of the column housing and discard it. Wash the JETSTAR column by applying 50 ml 
of wash buffer E5. Let the wash buffer flow through the column by gravity flow until 
all liquid has passed through the resin. Do not force out any remaining buffer! 
 
7.)  Remove the waste tray and place a clean, sterile collection tube under the outlet nozzle 
of the JETSTAR 2.0 column. Elute the DNA from the column into the clean tube 
with 15 ml of elution buffer E6. Precipitate the DNA by mixing the eluate 
thoroughly with 0.7 vols. of isopropanol. 
 
8.)  Spin down the DNA for 30 min at ³12.000 g at 4°C. If centrifuged in glass tubes (e.g. 
CorexÒ), the plasmid DNA tends to be very "sticky" and may spread over the whole 
wall of the centrifuge tube if a fixed angle rotor is used. Therefore we recommend 
either the use of a swing out rotor (i.e. HB-4 or HB-6 for Sorvall centrifuges), or, if 
such a rotor is not available, the siliconization of the centrifuge tubes with 
dimethyldichlorosilane. After precipitation the DNA is washed with 70-80% ethanol 
and briefly dried for 5 - 10 min either at elevated temperatures (50 – 60°C) or under 
vacuum (be careful when using a speed vac evaporator !!!). Dissolve the DNA in 
a suitable amount of 10 mM Tris-HCl or TE buffer (pH 8.0 – 8.5) or simply water. 
 8
 Protocol for Quik-Change XL-site-directed mutagenesis kit (Stratagene) 
 
Mutant Strand Synthesis Reaction (Thermal Cycling): 
 
1.  Synthesize two complementary oligonucleotides containing the desired mutation, 
flanked by unmodified nucleotide sequence. Purify these oligonucleotide primers prior 
to use in the following steps (see Mutagenic Primer Design). 
 
2.  Prepare the control reaction as indicated below: 
5 μl of 10× reaction buffer 
2 μl (10 ng) of pWhitescript 4.5-kb control plasmid (5 ng/μl) 
1.25 μl (125 ng) of oligonucleotide control primer #1 [34-mer (100 ng/μl)] 
1.25 μl (125 ng) of oligonucleotide control primer #2 [34-mer (100 ng/μl)] 
1 μl of dNTP mix 
3 μl of QuikSolution reagent 
36.5 μl of double-distilled water (ddH2O) to a final volume of 50 μl 
 
Then add 
 
1 μl of PfuUltra HF DNA polymerase (2.5 U/μl) 
 
3.  Prepare the sample reaction(s) as indicated below: 
Note Stratagene recommends setting up an initial sample reaction using 10 ng of dsDNA template. 
If this initial reaction is unsuccessful, set up a series of sample reactions using various concentrations of 
dsDNA template ranging from 5 to 50 ng (e.g., 5, 10, 20, and 50 ng of dsDNA template) while 
keeping the primer concentration constant. 
5 μl of 10× reaction buffer 
X μl (10 ng) of dsDNA template 
X μl (125 ng) of oligonucleotide primer #1 
X μl (125 ng) of oligonucleotide primer #2 
1 μl of dNTP mix 
3 μl of QuikSolution 
ddH2O to a final volume of 50 μl 
 
Then add 
 
1 μl of PfuUltra HF DNA polymerase (2.5 U/μl) 
 
4.  If the thermal cycler to be used does not have a hot-top assembly, overlay each 
reaction with ~30 μl of mineral oil. 
 
5.  Cycle each reaction using the cycling parameters outlined in Table I. (For the control 
reaction, use a 5-minute extension time and run the reaction for 12 cycles.) 
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 Note It is important to adhere to the 18-cycle limit when cycling the mutagenesis reactions. More that 
18 cycles can have deleterious effects on the reaction efficiency. 
 
6.  Following temperature cycling, place the reaction tubes on ice for 2 minutes to cool 
the reactions to ≤37°C. 
Note If desired, amplification may be checked by electrophoresis of 10 μl of the product on a 1% 
agarose gel. A band may or may not be visualized at this stage. In either case proceed with Dpn I 
digestion and transformation. 
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 Protocol for transfection of HepG2 cells (each in duplicate) 
Tube nr. Plasmid DNA (0.1 µg) (μl) pRL-null (0,1 µg) (μl) H2O (μl) FuGene (μl) Medium (μl) 
1 pGL3 control 1.0 2.3 6.8 1.2 38.8 
2 pGL3 basic 0.5 2.3 7.2 1.2 38.8 
3 WT DNA 1.1 2.3 6.7 1.2 38.8 
Tube nr. Plasmid DNA (0.2 µg) (μl) pRL-null (0.1 µg) (μl) H2O (μl) FuGene (μl) Medium (μl) 
4 pGL3 control 2.0 2.3 5.8 1.8 38.2 
5 pGL3 basic 1.0 2.3 6.7 1.8 38.2 
6 WT DNA 2.2 2.3 5.6 1.8 38.2 
Tube nr. Plasmid DNA (0.5 µg) (μl) pRL-null (0.1 µg) (μl) H2O (μl) FuGene (μl) Medium (μl) 
7 pGL3 control 5.0 2.3 2.8 3.6 36.4 
8 pGL3 basic 2.6 2.3 5.2 3.6 36.4 
9 WT DNA 5.5 2.3 2.3 3.6 36.4 
Tube nr. Plasmid DNA (0.1 µg) (μl) pRL-null (0.2 µg) (μl) H2O (μl) FuGene (μl) Medium (μl) 
10 pGL3 control 1.0 4.5 4.5 1.8 38.2 
11 pGL3 basic 0.5 4.5 5.0 1.8 38.2 
12 WT DNA 1.1 4.5 4.4 1.8 38.2 
Tube nr. Plasmid DNA (0.2 µg) (μl) pRL-null (0.2 µg) (μl) H2O (μl) FuGene (μl) Medium (μl) 
13 pGL3 control 2.0 4.5 3.5 2.4 37.2 
14 pGL3 basic 1.0 4.5 4.5 2.4 37.2 
15 WT DNA 2.2 4.5 3.3 2.4 37.2 
Tube nr. Plasmid DNA (0.5 µg) (μl) pRL-null (0.2 µg) (μl) H2O (μl) FuGene (μl) Medium (μl) 
16 pGL3 control 5.0 4.5 0.5 4.2 35.8 
17 pGL3 basic 2.6 4.5 2.9 4.2 35.8 
18 WT DNA 5.5 4.5 0.0 4.2 35.8 
       
FuGene 6 Reagent: DNA amounts (3:1)  
     
       
        
Concentration 
(µg/µl) 
Dilution  
(1/x) 
Conc.after 
dilution (µg/µl) 
pGL3 control    1.01 5 0.20 
pGL3 basic    0.39 1 0.39 
WT DNA   1.65 9 0.18 
pRL-null     2.22 25 0.09 
 
       
FuGene mastermix (x 3.5):      
  
  
  
  
Tube 1-3:   4.2 μl Fugene + 135.8 μl serum free medium  
Tube 4-6 and 10-12:  12. 6 μl Fugene + 267.4 μl serum free medium  
Tube 7-9:   12.6 μl Fugene + 133.7 μl serum free medium  
Tube 13-15:   8.4 μl Fugene + 131.6 μl serum free medium  
Tube 16-18:   14.7 μl Fugene + 125.3 μl serum free medium    
       
 
Mix the contents (do not vortex). Incubate for 30 min at RT. Dropwise add the mixture from each tube into the wells 
(dublicate for each tube). Swirl the wells to ensure even dispersal. Incubate cells in incubator for 24 hours. 
 
 
In each tube: 20 µl mastermix for each sample, then add 5 µl premixed pRL-null, DNA and H2O. 
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  iv
Appendix D 
• Raw data from luciferase assay. 
 
  
Well Sample name luc pRL null luc/Renhilla Mean Conc.  Luc/Renhilla*100 Mean  Propotion plasmid/basic 
A1 control 3337 371 9.0     899.5   
A2 control 1724 273 6.3    7.7    631.5    765.5                31.2  
A3 basic 88 390 0.2     22.6    
A4 basic 81 305 0.3    0.2    26.6     24.6                 1.0  
A5 WT DNA 124 307 0.4     40.4    
A6 WT DNA 118 270 0.4    0.4  0.1 pRL 0.1 plasmid 43.7     42.0                 1.7  
A7 control 150071 3399 44.2     4415.2    
A8 control 75906 2175 34.9   39.5   3489.9   3.952.5                495.1  
A9 basic 568 7401 0.1     7.7    
A10 basic 379 4570 0.1    0.1    8.3      8.0                 1.0  
A11 WT DNA 8953 6082 1.5     147.2    
A12 WT DNA 4634 2921 1.6    1.5  0.1 pRL 0.2 plasmid 158.6    152.9                19.2  
B1 control 713769 4220 169.1     16914.0    
B2 control 564106 3660 154.1  161.6   15412.7  16.163.3                716.4  
B3 basic 1391 5941 0.2     23.4    
B4 basic 930 4284 0.2    0.2    21.7     22.6                 1.0  
B5 WT DNA 16841 3930 4.3     428.5    
B6 WT DNA 12317 2672 4.6    4.4  0.1 pRL 0.5 plasmid 461.0    444.7                19.7  
B9 control 159590 11079 14.4     1440.5    
B10 control 84744 8217 10.3   12.4   1031.3   1.235.9                572.1  
B11 basic 239 10763 0.0     2.2    
B12 basic 217 10332 0.0   0.02   2.1      2.2                 1.0  
C1 WT DNA 3154 9412 0.3     33.5    
C2 WT DNA 2192 5403 0.4    0.4  0.2 pRL 0.1 plasmid 40.6     37.0                17.1  
C3 control 376713 10792 34.9     3490.7    
C4 control 272217 9550 28.5   31.7   2850.4   3.170.6                653.8  
C5 basic 437 9173 0.0     4.8    
C6 basic 402 8147 0.0    0.0    4.9      4.8                 1.0  
C7 WT DNA 7093 8349 0.8     85.0    
C8 WT DNA 3989 5356 0.7    0.8  0.2 pRL 0.2 plasmid 74.5     79.7                16.4  
C9 control 241331 5506 43.8     4383.1    
C10 control 256876 5494 46.8   45.3   4675.6   4.529.3                330.6  
C11 basic 1265 9140 0.1     13.8    
C12 basic 1089 8029 0.1    0.1    13.6     13.7                 1.0  
D1 WT DNA 19952 11073 1.8     180.2    
D2 WT DNA 8597 3719 2.3    2.1  0.2 pRL 0.5 plasmid 231.2    205.7                15.0  
Plasmid denotes pGL3 control, pGL3 basic or WT DNA. 
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